SCHEMBL7185635

SCHEMBL7185635

Cc1ccc(PC(=O)c2c(Cl)cccc2Cl)c(C)c1.[LiH]

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.39
GAA P10253 3/20 0.38
TAS1R3 Q7RTX0 2/20 0.38
TAS1R1 Q7RTX1 2/20 0.38
TAS1R2 Q8TE23 2/20 0.38
POLB P06746 1/20 0.38
PTGS2 P35354 2/20 0.36
RAB9A P51151 3/20 0.36
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
LMNA P02545 2/20 0.35
KDM4E B2RXH2 1/20 0.35
TYK2 P29597 1/20 0.35
PBRM1 Q86U86 1/20 0.35
ITGB1 P05556 1/20 0.35
ITGA4 P13612 1/20 0.35
MAPT P10636 1/20 0.35
FABP3 P05413 1/20 0.34
FABP4 P15090 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Lithium SCHEMBL7185641 0.97 ALDH1A1 (0.39) ALDH1A1GAATAS1R3TAS1R1TAS1R2
SCHEMBL7183079 0.96 TYK2 (0.39) ALDH1A1GAATAS1R3TAS1R1TAS1R2
Lithium SCHEMBL7183080 0.93 TYK2 (0.39) ALDH1A1GAATAS1R3TAS1R1TAS1R2
SCHEMBL7189927 0.91 TAS1R3 (0.41) ALDH1A1GAATAS1R3TAS1R1TAS1R2
Lithium SCHEMBL7189940 0.88 TAS1R3 (0.41) ALDH1A1GAATAS1R3TAS1R1TAS1R2
SCHEMBL7177506 0.88 ALDH1A1 (0.39) ALDH1A1GAATAS1R3TAS1R1TAS1R2
SCHEMBL7180437 0.87 NFE2L2 (0.36) ALDH1A1GAARAB9AMEN1KMT2A
SCHEMBL10870076 0.86 ALDH1A1 (0.40) ALDH1A1GAATAS1R3TAS1R1TAS1R2
Lithium SCHEMBL7177510 0.84 ALDH1A1 (0.39) ALDH1A1GAATAS1R3TAS1R1TAS1R2
Lithium SCHEMBL7180446 0.84 NFE2L2 (0.36) ALDH1A1GAARAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 ALDH1A1 3416/4885GAA 4753/4885TAS1R3 2990/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 ALDH1A1 3984/4885GAA 4793/4885TAS1R3 3176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.